Disclosures for "NF1 Recommendation-Based Care Delivery: A Survey of Patients and Caregivers")
-
Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Navio Theragnostics. Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Recursion Pharmaceuticals, Inc. Dr. Jordan has received personal compensation in the range of $0-$499 for serving as a Consultant for Guidepoint. Dr. Jordan has received personal compensation in the range of $0-$499 for serving as a Consultant for Atheneum Partners. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CEC Oncology. Dr. Jordan has received personal compensation in the range of $0-$499 for serving as a Consultant for EM Partners. Dr. Jordan has received personal compensation in the range of $0-$499 for serving as a Consultant for GLG. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Texas Health Resources. Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Recursion Pharmaceuticals. Dr. Jordan has stock in Navio Theragnostics. Dr. Jordan has stock in The Doctor Lounge. The institution of Dr. Jordan has received research support from The Burke Foundation. The institution of Dr. Jordan has received research support from NIH. The institution of Dr. Jordan has received research support from Department of Defense. Dr. Jordan has received publishing royalties from a publication relating to health care. Dr. Jordan has a non-compensated relationship as a board member with United Council for Neurologic Subspecialties that is relevant to AAN interests or activities. Dr. Jordan has a non-compensated relationship as a board member with Neurofibromatosis Northeast that is relevant to AAN interests or activities. Dr. Jordan has a non-compensated relationship as a board member with ABA Academy that is relevant to AAN interests or activities. Dr. Jordan has a non-compensated relationship as a chair, scientific advisory board with Neurofibromatosis Network that is relevant to AAN interests or activities.
-
The institution of Vanessa Merker has received research support from Children's tumor foundation . The institution of Vanessa Merker has received research support from NF Northeast. Vanessa Merker has received personal compensation in the range of $10,000-$49,999 for serving as a science writer with Neurofibromatosis Network.
-
Lori B. Chibnik has nothing to disclose.
-
Ms. Ma has nothing to disclose.
-
Dr. Ullrich has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Astra Zeneca. Dr. Ullrich has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Wolf, Horowitz & Etlinger, LLC. The institution of Dr. Ullrich has received research support from Children's Tumor Foundation. Dr. Ullrich has received intellectual property interests from a discovery or technology relating to health care. Dr. Ullrich has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Yohay has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra Zeneca. Dr. Yohay has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Yohay has received publishing royalties from a publication relating to health care.
-
Pamela Knight has received personal compensation for serving as an employee of Children's Tumor Foundation.
-
Heather Radtke has received personal compensation for serving as an employee of Children's Tumor Foundation.
-
Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NFlection Therapeutics. Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Akouos. Dr. Plotkin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SonALAsense. Dr. Plotkin has stock in NFlection Therapeutics. Dr. Plotkin has stock in NF2 Therapeutics. Dr. Plotkin has received research support from Children's Tumor Foundation. Dr. Plotkin has received research support from Department of Defense. Dr. Plotkin has received research support from National Institutes of Health. Dr. Plotkin has received intellectual property interests from a discovery or technology relating to health care.